Navigation Links
TPI to Hold 2011 Shareholder Annual Meeting on April 11, 2012 in New York City
Date:1/24/2012

CHENGDU, China, Jan. 24, 2012 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today announced that the Company's 2011 Annual Shareholder Meeting will be held at Floor 20, 17 State Street, New York, NY 10004 on Wednesday, April 11, 2012, at 10:00 am (EST).  

TPI's Board of Directors has established Monday, February 13, 2012, as the record date for determining the stockholders entitled to vote at the Annual Meeting.

Stockholder proposals must be received no later than Friday, February 17, 2012, in order to be considered for inclusion in the Company's proxy statement or to be presented at the Annual Meeting. Stockholder proposals should be mailed to Hunter Taubman Weiss LLP, c/o Tianyin Pharmaceutical Co., Inc, 17 State Street, Floor 20, New York, NY 10004.

About TPI

Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, mTCM, branded generics and API. TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list of China. TPI's pipeline targets various high incidence healthcare indications. TPI has an extensive nationwide distribution network with a sales force of 730 sales representatives out of totaled 1,365 employees.

For more information about TPI, please visit:  http://www.tianyinpharma.com.

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

For more information, please visit: http://www.tianyinpharma.com, or email ir@tpi.asia

Tel:     +86-28-8551-6696 (Chengdu, China)
          +86-134-3655-0011 (China)

Address:
Tianyin Pharmaceutical
23rd Floor, Unionsun Yangkuo Plaza
No. 2, Block 3, South Renmin Road
Chengdu, 610041
China


'/>"/>
SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. GeoVax Labs CEO Update Letter to Shareholders
2. Ampio Pharmaceuticals Schedules Webcast to Update Shareholders
3. Leatt Holds 2011 Annual Meeting of Shareholders
4. IsZo Capital Writes to Taro Pharmaceutical Board Commenting on Management Proposals for 2011 Annual Shareholder Meeting; Reflecting on Sun Pharmas Response to Similar 2009 Proposals
5. Medco Shareholders Approve Merger With Express Scripts
6. Nutra Pharma Letter to Shareholders
7. GP Strategies Shareholders Approve Elimination of Holding Company Structure and Renaming of General Physics Corporation
8. IzSo Capital Writes to Taro Pharmaceutical Board Demanding that Liability Protection Management Proposals be Removed Immediately from Agenda for Annual Shareholders Meeting
9. Leatt Corporation Announces 2011 Annual Shareholders Meeting
10. Concord Medical Announces Shareholder Resolutions Adopted at 2011 Annual General Meeting, Board and Management Changes
11. Aethlon Medical Releases Shareholder Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... DIEGO , Dec. 9, 2016 aTyr Pharma, Inc. ... discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, ... at the upcoming BMO Prescriptions for Success Healthcare Conference at the ... on Wednesday, December 14, 2016, at 4:20 p.m. ET. ... ...
(Date:12/9/2016)... , Dec. 9, 2016  Axovant Sciences Ltd. ... biopharmaceutical company focused on the treatment of dementia, ... from a Phase 2b trial evaluating treatment with ... compared with donepezil plus placebo in people with ... addition of intepirdine to treatment was associated with ...
(Date:12/8/2016)... , Dec. 8, 2016 Australia Glaucoma ... GlobalData,s new report, "Australia Glaucoma Surgery Devices ... on the Australia Glaucoma Surgery Devices market. The ... volume (in units) and average prices (USD) within ... report also provides company shares and distribution shares ...
Breaking Medicine Technology:
(Date:12/9/2016)... NY (PRWEB) , ... December 09, 2016 , ... ... and Drug Dependence, Inc. (NCADD) is recommending the film Whispering Spirits ... and the District of Columbia as an education tool in the war against teen ...
(Date:12/9/2016)... ... December 09, 2016 , ... ... Pierre Hotel in New York, NY, on December 3rd, to benefit Holy Name ... attended the annual event, which raised over $1 million - the largest event ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Quality Insights beginning January 1, 2017. The name change aligns the entire ... measuring and improving health care quality. , “We are very proud of the ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... pleased to announce that “Natural Language Processing–Enabled and Conventional Data Capture Methods for ... JMIR Medical Informatics . , Results of the comparative usability study demonstrate ...
(Date:12/8/2016)... ... ... With the increasing demand for dental implants, the National Association of Dental ... dentists and patients about the safety issues related to dental restorations. According to the ... is projected to reach $6.4 billion in 2018 with more than 30 million Americans ...
Breaking Medicine News(10 mins):